AAS
ICPT

Ameritas Advisory Services’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Ameritas Advisory Services’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-450
Closed -$8.53K – 2682
2023
Q1 		$8.53K Buy
+450
New +$7.79K ﹤0.01% 1951

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Ameritas Advisory Services's ICPT Position: Q2 2023 in Review

Ameritas Advisory Services sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 450 shares — an estimated $8.53K sold.

Ameritas Advisory Services first reported a position in ICPT in Q1 2023 and held it in 1 quarter. The position peaked at $8.53K in Q1 2023. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

  • Ameritas Advisory Services reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Ameritas Advisory Services sold 450 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $8.53K.
  • Ameritas Advisory Services first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2023 and held it in 1 quarter.
  • Ameritas Advisory Services's Intercept Pharmaceuticals, Inc. position peaked at $8.53K in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Ameritas Advisory Services's 13F filing for Q2 2023, filed 25 Jul 2023.